Kooky_Edge5717 t1_iycfqht wrote on November 30, 2022 at 10:49 AM

Reply to comment by arsenal09490 in Alzheimer’s Drug In Development, Lecanemab, May Benefit Some Patients But Carries Risks of Brain Swelling and Bleeding by Relevant_synapse

I’m not familiar with the various tools/scores, and I won’t be able to check the full paper for a while. Do you happen to know the minimum clinically important difference in any of the scores?

Relevant_synapse OP t1_iycgkru wrote on November 30, 2022 at 11:00 AM

In general, the MCIDs for the measures they reported are larger than the effect size of this drug.

1-2 for the CDR sum of boxes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690415/

3 points on the ADAS-Cog (70 point scale), not sure about the Cog14 (90 point scale) https://pubmed.ncbi.nlm.nih.gov/22019547/

0.05 points for MCI and 0.1 for dementia on the ADCOMS (range from 0 to 1): https://pubmed.ncbi.nlm.nih.gov/35513767/

Looking into the other measures later